Genomic landscape of treatment-naïve urological cancers using next-generation sequencing-based panel test in the Japanese population

Int J Urol. 2022 Aug;29(8):909-911. doi: 10.1111/iju.14927. Epub 2022 May 24.

Kosuke Mizutani^{1

2}, Kouseki Hirade¹, Seiji Sugiyama³, Yasutaka Kato⁴, Hiroshi Nishihara^{4

5}, Satoshi Ishihara^{1

2}

¹ Cancer Genomic Testing and Treatment Center, Central Japan International Medical Center, Minokamo, Gifu, Japan.
² Departments of, Urology, Central Japan International Medical Center, Minokamo, Gifu, Japan.
³ Departments of, Pathology, Central Japan International Medical Center, Minokamo, Gifu, Japan.
⁴ Genomics Unit, Keio Cancer Center, Keio University School of Medicine, Shinjuku, Tokyo, Japan.
⁵ Department of Biology and Genetics, Laboratory of Cancer Medical Science, Hokuto Hospital, Obihiro, Hokkaido, Japan.

No abstract available

Keywords: genome profiling; next-generation sequencing; prostate cancer; renal cell carcinoma; urothelial carcinoma.

MeSH terms